Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51

Vaccine

Volumn 29, Issue 14, 2011, Pages 2607-2612

  Eder, Susanne ^a   Dubischar Kastner, Katrin ^a   Firbas, Christa ^b   Jelinek, Tomas ^c   Jilma, Bernd ^b   Kaltenboeck, Astrid ^a   Knappik, Michael ^c   Kollaritsch, Herwig ^b   Kundi, Michael ^d   Paulke Korinek, Maria ^b   Schuller, Elisabeth ^a   Klade, Christoph S ^a  

^a INTERCELL AG   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Berlin Center for Travel and Tropical Medicine   (Germany)

^d Medical University of Vienna   (Austria)

Author keywords

Ixiaro; Japanese Encephalitis virus; Jespect; Phase III clinical trial; Vaccination

Indexed keywords

JAPANESE ENCEPHALITIS VACCINE; JESPECT; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY TITER; ARTICLE; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE TENDERNESS; JAPANESE ENCEPHALITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; VACCINATION REACTION; VIRUS NEUTRALIZATION; VIRUS PLAQUE;

ADULT; AGED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENCEPHALITIS, JAPANESE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION, SECONDARY; JAPANESE ENCEPHALITIS VACCINES; MALE; MIDDLE AGED; NEUTRALIZATION TESTS; PLAQUE ASSAY;

EID: 79952248906     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.058     Document Type: Article

References (27)

1. Solomon T. Control of Japanese encephalitis-within our grasp?. N Engl J Med 2006, 355:869-871.
2. Parida M., Dash P.K., Tripathi N.K., Ambudj, Sannarangaiah S., Saxena P., et al. Japanese encephalitis outbreak, India, 2005. Emerg Infect Dis 2006, 12:1427-1430.
3. Solomon T., Whitley R.J. Arthropod-borne viral encephalitides. Infections of the central nervous system 2004, Lippincott Williams and Wilkins, Philadelphia. 2nd ed. M. Scheld, R.J. Whitley, C. Marra (Eds.).
4. Tauber E., Kollaritsch H., Korinek M., Rendi-Wagner P., Jilma B., Firbas C., et al. Safety and immunogenicity of a Vero-cell-derived, inactivated Japanese encephalitis vaccine: a non-inferiority, phase III, randomised controlled trial. Lancet 2007, 370:1847-1853.
5. Tauber E., Kollaritsch H., von Sonnenburg F., Lademann M., Jilma B., Firbas C., et al. Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine. J Infect Dis 2008, 198:493-499.
6. Schuller E., Jilma B., Voicu V., Golor G., Kollaritsch H., Kaltenboeck A., et al. Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 six and 12 month results of a multicenter follow-up phase 3 study. Vaccine 2008, 26:4382-4386.
7. Schuller E., Klade C.S., Wolfl G., Kaltenboeck A., Dewasthaly S., Tauber E. Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled phase 3 study. Vaccine 2009, 27:2188-2193.
8. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005, 23:5205-5211.
9. Kaltenboeck A., Dubischar-Kastner K., Schuller E., Datla M., Klade C.S., Kishore T.S. Immunogenicity and safety of IXIARO (IC51) in a phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010, 28:834-839.
10. 14-14-2): results of a randomized trial with 26,239 subjects. J Infect Dis 1997, 176:1366-1369.
11. 14-14-2 Japanese encephalitis vaccine--a comparison of 1- and 3-month immunization schedules. J Infect Dis 1998, 177:221-223.
12. Altman D., Machin D., Bryant T., Gardner M. Statistics with confidence 2000, BMJ Books, Bristol. 2nd ed.
13. Oya A., Kurane I. Japanese encephalitis for a reference to international travelers. J Travel Med 2007, 14:259-268.
14. Rendi-Wagner P., Paulke-Korinek M., Kundi M., Wiedermann U., Laaber B., Kollaritsch H. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine 2007, 25:5097-5101.
15. Paulke-Korinek M., Rendi-Wagner P., Kundi M., Laaber B., Wiedermann U., Kollaritsch H. Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection. Vaccine 2009, 27:7027-7030.
16. Wright P.F., Ankrah S., Henderson S.E., Durbin A.P., Speicher J., Whitehead S.S., et al. Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers. Vaccine 2008, 26:882-890.
17. Schuller E., Klade C.S., Heinz F.X., Kollaritsch H., Rendi-Wagner P., Jilma B., et al. Effect of pre-existing anti-tick-borne encephalitis virus immunity on neutralising antibody response to the Vero cell-derived, inactivated Japanese encephalitis virus vaccine candidate IC51. Vaccine 2008, 26:6151-6156.
18. Gambel J.M., DeFraites R., Hoke C., Brown A., Sanchez J., Karabatsos N., et al. Japanese encephalitis vaccine: persistence of antibody up to 3 years after a three-dose primary series. J Infect Dis 1995, 171:1074.
19. Hanna J.N., Smith G.A., McCulloch B.G., Taylor C.T., Pyke A.T., Brookes D.L. An assessment of the interval between booster doses of Japanese encephalitis vaccine in the Torres Strait. Aust N Z J Public Health 2005, 29:44-47.
20. 14-14-2 Japanese encephalitis vaccine: immunogenicity and anamnestic responses. Vaccine 2008, 26:1638-1643.
21. Tandan J.B., Ohrr H., Sohn Y.M., Yoksan S., Ji M., Nam C.M., et al. Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. Vaccine 2007, 25:5041-5045. drjbtandan@yahoo.com.
22. Sohn Y.M. Japanese encephalitis immunization in South Korea: past, present, and future. Emerg Infect Dis 2000, 6:17-24.
23. National Health and Medical Research Council Japanese encephalitis. The Australian immunisation handbook 2000, AGPS, Canberra (ACT). 7 ed.
24. Dubischar-Kastner K., Eder S., Buerger V., Gartner-Woelfl G., Kaltenboeck A., Schuller E., et al. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO. IC51. Vaccine 2010, 28:5197-5202.
25. Global Advisory Committee on vaccine safety, 9-10 June 2005. Weekly Epidemiol Rec 2005, 80:242-247.
26. Marfin A.A., Eidex R.S., Kozarsky P.E., Cetron M.S. Yellow fever and Japanese encephalitis vaccines: indications and complications. Infect Dis Clin North Am 2005, 19:151-168. ix.
27. Ruff T.A., Eisen D., Fuller A., Kass R. Adverse reactions to Japanese encephalitis vaccine. Lancet 1991, 338:881-882.